Madrid, October 5, 2018 - SIFI, the leading Italian ophthalmic pharmaceutical company, widely recognized in the development of innovative solutions for eye diseases, is pleased to announce the opening of SIFI IBERICA SL, a new wholly owned Spanish subsidiary, located in Madrid.
The latest SIFI branch has been created with the aim of directly managing the marketing of its Pharma and Surgical products in Spain, one of the largest and most competitive markets in Western Europe. This is intended to further consolidate the group's international expansion strategy, building on its R&D know-how, that generated various innovations and 100 patents worldwide, and its manufacturing facilities, already devoted to international markets for 60% of their overall output. SIFI exports towards more than 20 countries, mainly European and Asian ones, with a turnover in international markets that almost doubled in the last four years.
"In the last two years we have invested very rapidly in the development of a direct commercial and logistics presence in some European countries." said Fabrizio Chines, President and CEO SIFI. "In Spain we see good opportunities for our existing portfolio and pipeline, and we are ready to offer a full range of innovative therapeutic solutions to Spanish ophthalmologists, surgeons and patients, leveraging on over 80 years of history and know-how in Ophthalmology".
SIFI is the leading Italian ophthalmic company, focused on eye care since 1935. SIFI designs, manufactures and markets innovative pharmaceutical specialty products, nutraceuticals, surgical and medical devices. Headquartered in Catania, Sicily, SIFI operates directly in Italy, France, Romania and Mexico with a staff of more than 370 people worldwide. Since June 2015, SIFI is backed by the private equity 21 Investimenti to support the company’s international expansion and portfolio development strategy. More information available at www.sifigroup.com.
Press & Communication SIFI
Ada Puglisi 0039 095 7922145